Expert Point of View: Clifford A. Hudis, MD

Get Permission

“This is the beginning of an exciting new chapter in the treatment of cancer,” commented Clifford A. Hudis, MD, President-Elect of ASCO and moderator of the press briefing. “These studies focus on our ability to productively manipulate the immune system by targeting PD-L1 and PD-1, which allows the body’s natural immunity to ramp up and target cancer.”

Dr. Hudis noted that while phase I studies historically evaluate safety only, the phase I data for MPDL3280A already show evidence of efficacy, with responses lasting more than 1 year in heavily pretreated patients. “The clearest indications of activity were in non–small cell lung cancer and melanoma, and in tumors testing positive for the marker, suggesting that maybe in the future we can develop a biomarker that identifies tumors that will be more responsive to this approach,” he suggested. ■

Disclosure: Dr. Hudis reported no potential conflicts of interest.

Related Articles

Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies

Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...

SIDEBAR: Understanding the PD-1/PD-L1 Pathway and Its Promise

Tumors can be recognized by the immune system, but they have multiple mechanisms for evading eradication by the immune system. The tumor microenvironment suppresses the immune response, partly because tumors can express molecules that inhibit immune responses. The cancer clinical trials summarized...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.